Delta-Fly Pharma Reports Massive Exercise

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 26, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Delta-Fly Pharma Reports Massive Exercise of Warrant Shares

Source disclosure: February 26, 2026, 16:10 JST Delta-Fly Pharma,Inc. [4598.T] TOKYO, Feb 26 (Pulse News Wire) -- Delta-Fly Pharma, Inc. (4598.T), represented by President Sei Eshima, has announced significant exercise activity related to its Eleventh Tranche Warrant (with Exercise Price Adjustment Clause) issued on February 2, 2026, to Macquarie Bank Limited. The warrant exercises occurred between February 3 and February 26, 2026. According to the company's announcement, during t